The experience accumulated in the field of cancer therapy with immune checkpoint inhibitors provides evidence that the microbiota govern the balance between CD8+ T cell activation and inflammation on one side and CD4+/FoxP3+ T reg cells and lack of inflammation on the other side. This evidence concerns the gene FOXP3 and cancer.